Jantung yang Tidak Tahu Sedang Diobati: Kardiotoksisitas Anthracycline dan Urgensi Kardio-Onkologi

Raymond R. Tjandrawinata

doi:10.56951/49s0cn95

Jantung yang Tidak Tahu Sedang Diobati: Kardiotoksisitas Anthracycline dan Urgensi Kardio-Onkologi

Penulis

Raymond R. Tjandrawinata School of Bioscience, Technology and Innovation, Atma Jaya Catholic University of Indonesia, Jakarta, Indonesia

DOI:

https://doi.org/10.56951/49s0cn95

Editorial

Kemoterapi berbasis anthracycline telah lama menjadi andalan tata laksana beberapa jenis keganasan, namun, kelompok
obat antineoplastik ini membawa konsekuensi yang sering terlambat disadari berupa kerusakan jantung subklinis, jauh
sebelum menunjukkan manifestasi klinis. Kardiotoksisitas yang dimediasi oleh disfungsi topoisomerase IIβ dan stres
oksidatif tidak terjadi secara dramatis, melainkan secara kumulatif, dengan insiden sekitar 9% pada populasi yang
terpapar. Paradoks fisiologis meningkatkan kompleksitas fenomena ini, di mana mekanisme kompensasi jantung justru
menyembunyikan kerusakan yang sedang berlangsung, sehingga jendela intervensi dini sering terlewat. Artikel ini
berargumen bahwa batas tradisional antara onkologi dan kardiologi tidak lagi memadai, dan bahwa pendekatan kardioonkologi yang terintegrasi, dengan pemantauan aktif sejak awal terapi, merupakan suatu keharusan klinis, bukan pilihan konsultatif.

Unduhan

Baca Selengkapnya

Referensi

1. Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015;131(22):1981–8. doi:10.1161/CIRCULATIONAHA.114.013777.

2. Yeh ETH, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol. 2009;53(24):2231–47. doi:10.1016/j.jacc.2009.02.050.

3. Curigliano G, Cardinale D, Suter T, Plataniotis G, de Azambuja E, Sandri MT, et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol. 2012;23(Suppl 7):v155–66. doi:10.1093/annonc/mdw293.

4. Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy. J Am Soc Echocardiogr. 2014;27(9):911–39. doi:10.1016/j.echo.2014.07.012.

5. Zhang S, Liu X, Bawa-Khalfe T, Lu LS, Lyu YL, Liu LF, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med. 2012;18(11):1639–42. doi:10.1038/nm.2919.

6. Octavia Y, Tocchetti CG, Gabrielson KL, Janssens S, Crijns HJ, Moens AL. Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol. 2012;52(6):1213–25. doi:10.1016/j.yjmcc.2012.03.006.

7. Thavendiranathan P, Poulin F, Lim KD, Plana JC, Woo A, Marwick TH. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy. J Am Coll Cardiol. 2014;63(25):2751–68. doi:10.1016/j.jacc.2014.01.073.

8. Armenian SH, Lacchetti C, Lenihan D, Carver J, Constine LS, Denduluri N, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: ASCO Clinical Practice Guideline. J Clin Oncol. 2017;35(8):893–911. doi:10.1200/JCO.2016.70.5400.

9. Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M, et al. 2016 ESC position paper on cancer treatments and cardiovascular toxicity. Eur Heart J. 2016;37(36):2768–801. doi:10.1093/eurheartj/ehw211.

10. Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 2022 ESC Guidelines on cardio-oncology. Eur Heart J. 2022;43(41):4229–361. doi:10.1093/eurheartj/ehac244.

11. Hermann J, Lerman A, Sandhu NP. Evaluation and management of patients with heart disease and cancer: cardio-oncology. Mayo Clin Proc. 2014;89(9):1287–306. doi:10.1016/j.mayocp.2014.05.013.